Document Classification

Section Type: RESULTS

Text: The results of the 12-week study of dupilumab monotherapy reproduced and extended the 4-week findings : 85 % of patients in the dupilumab group, as compared with 35 % of those in the placebo group, had a 50 % reduction in the EASI score (EASI-50, with higher scores in the EASI indicating greater severity of eczema) (P < 0. 001) ; 40 % of patients in the dupilumab group, as compared with 7 % in the placebo group, had a score of 0 to 1 (indicating clearing or near-clearing of skin lesions) on the investigator 's global assessment (P < 0. 001) ; and pruritus scores decreased (indicating a reduction in itch) by 55. 7 % in the dupilumab group versus 15. 1 % in the placebo group (P < 0. 001).